Abstract:Funding Acknowledgements Type of funding sources: None. Background Epicardial adipose tissue (EAT) has garnered attention as a potential imaging biomarker for the risk stratification of cardiovascular diseases (CVD). However, the prognostic utility of EAT due to inter-ethnic differences and imaging modality (computed tomography (CT) or transthoracic echocardiography (TTE)) remains undetermined. Purpose To evaluate the effect of EAT volume and thickness on cardiovascular and cerebrovascular outcomes. We also aim to compare the prognostic utility between CT volumetric and TTE thickness quantification; and provide consolidated data on the heterogeneity in EAT measurements across different ethnic groups. Methods Medline and Embase databases were searched from inception till 16 May 2022 for studies that measured EAT volume or thickness of adult patients at baseline and reported follow-up data on outcomes of interest. Outcomes included MACE, all-cause mortality, cardiac death, myocardial infarction (MI), coronary revascularisation, atrial fibrillation (AF), and stroke. Statistical analyses were conducted on Review Manager 5.4.1 to obtain unadjusted and adjusted hazard ratios (HR) and odds ratios (OR) with the results presented on forest plots. Results Twenty-nine studies comprising 19709 patients were included in our analysis. Increased EAT thickness and volume were associated with higher risks of MACE (adjusted HR [aHR] 1.46, 95%CI 1.25–1.71, p<0.001), cardiac death (OR 2.53, 95%CI 1.17–5.44, p=0.020), MI (OR 2.63, 95%CI 1.39–4.96, p=0.003), coronary revascularisation (OR 2.99, 95%CI 1.64–5.44, p<0.001), AF (aOR 4.04, 95%CI 3.06–5.32, p<0.001), and stroke (HR 1.02, 95%CI 1.01–1.03, p<0.001). CT-volumetric quantification of EAT conferred a larger MACE risk (aHR 1.79, 95%CI 1.47–2.17, p<0.001) compared to TTE thickness quantification (aHR 1.20, 95%CI 1.09–1.32, p<0.001). Studies originating from North America (HR 1.91, 95%CI 1.26–2.89, p=0.002) and Asia (HR 1.60, 95%CI 1.09–2.36, p=0.020) demonstrated a significantly higher risk of MACE with increased EAT thickness and volume. However, this significance was not seen in European studies (HR 1.48, 95%CI 0.99–2.20, p=0.060). Subgroup differences were also noted across the studies' countries of origin when analysing the association of EAT and MI (p=0.020). European studies reported a higher magnitude of MI risk associated with higher EAT thickness and volume (OR 5.28, 95%CI 2.34–11.95, p<0.001) as compared to Asian studies (OR 1.75, 95%CI 1.05–2.92, p=0.030). No differences were noted across other outcomes in the subgroup comparisons by geographical region and between CT and TTE quantification of EAT. Conclusion The utility of EAT as an imaging biomarker for predicting and prognosticating CVD is promising. Future efforts to harmonise the EAT parameter thresholds, based on the type of imaging modality and the target population's ethnic characteristics, will be the next important step before including EAT in CVD prediction models.

Effects of serum adipocytokine CTRP-9 and epicardial adipose tissue on metabolism syndrome

Clinical Significance and Serum Concentration of Inflammatory Factor and Adiponectin in Children with Metabolism Syndrome

Impact of Epicardial Adipose Tissue Volume on Hemodynamically Significant Coronary Artery Disease in Chinese Patients with Known or Suspected Coronary Artery Disease

Serum CTRP1 level and its relationship with serum adiponectin level in elderly male metabolic syndrome patients

Associations of C1q/TNF-Related Protein-9 Levels in Serum and Epicardial Adipose Tissue with Coronary Atherosclerosis in Humans

Correlation of serum visfatin and adiponectin levels with metabolic syndrome

The Effect of Epicardial Fat Volume in Patients with Metabolic Syndrome on Insulin Resistance and Coronary Heart Disease

Association between epicardial adipose tissue and myocardial work by non-invasive left ventricular pressure-strain loop in people with suspected metabolic syndrome

Association of Triglyceride with Serum Polyunsaturated Fatty Acid in Patients with Metabolic Syndrome

Visfatin and Adiponectin Levels in Metabolic Syndrome Patients and Their Influencing Factors

Truncal and Leg Fat Associations with Metabolic Risk Factors among Chinese Adults.

Serum CTRP9 and High-Molecular Weight Adiponectin Are Associated with Ischemic Stroke

Association of human epicardial adipose tissue volume, inflammatory mediators MMP9 with coronary positive remodeling

Association of epicardial adipose tissue with metabolic risk factors on cardiovascular outcomes: serial coronary computed tomography angiography study

Correlation of carotid artery atherosclerosis with C-reactive protein and adiponectin in patient with metabolic syndrome

Circulating CTRP7 Is a Potential Predictor for Metabolic Syndrome

Effects of epicardial adipose tissue volume and thickness assessed by computed tomography and echocardiography on cardiovascular and cerebrovascular outcomes: a systematic review and meta-analysis

Relationship between adipose cytokines and metabolic syndrome in newly diagnosed type 2 diabetes mellitus patients

The exercise tolerance dependence on epicardial fat thickness, right ventricular hypertrophy and right ventricular global function in patients with metabolic syndrome

Magnetic Resonance Imaging Assessment of Abdominal Ectopic Fat Deposition in Correlation With Cardiometabolic Risk Factors

Characterizing regional and global effects of epicardial adipose tissue on cardiac systolic and diastolic function